FDA approves 23andMe's genetic screening test for rare disorder

Google-backed 23andMe won U.S. approval to market direct-to-comsumer genetic test

(Reuters) - Google (NSDQ:GOOG)-backed 23andMe won

U.S. approval on Thursday to market the first direct-to-consumer

genetic test for a mutation that can cause children to inherit

Bloom syndrome, a rare disorder that leads to short height, an

increased risk of cancer and unusual facial features.

23andMe Inc., Google Inc.

News Well, Food & Drug Administration (FDA)

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1AcvINv